Diffuse large B-cell lymphomaNews & Research
14 curated articles for Diffuse large B-cell lymphoma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Cancer discovery May 17, 2026
SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities.
Diffuse large B-cell lymphomas (DLBCL) are genetically and phenotypically heterogeneous, making diagnosis and treatment challenging. Current models suggest DLBCL derive from follicular B cells engaged in adaptive immune responses. By studying co-occurring truncating mutations in SPEN and NOTCH2 in t...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Cancer medicine May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.
Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implicated in lymphoma pathogenesis and can be targeted by the small molecule TK216, which disrupts ETS-DHX...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Cells May 13, 2026
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
CD20 × CD3 bispecific antibodies (BsAbs) have emerged as a meaningful therapeutic option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), redirecting endogenous T cells against malignant B cells independently of major histocompatibility complex-mediated antigen presentation, an...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Cancer medicine May 11, 2026
Socioeconomic Status and Access to Treatment in Diffuse Large B-Cell Lymphoma.
Large B-cell lymphoma (LBCL) is the most common lymphoma subtype, with diffuse LBCL (DLBCL) accounting for 30%-40% of new lymphoma cases. The International Prognostic Index (IPI) is widely used for prognostic assessment in DLBCL. Clinical features associated with a poorer prognosis, such as advanced...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc Apr 17, 2026
Complexity and Challenges of Translating the Dark Zone Signature Into Immunohistochemistry in Diffuse Large B-Cell Lymphoma.
Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBCL-MYC/BCL2) is a distinct disease entity with worse prognosis and is usually diagnosed with identification of MYC and BCL2 rearrangements by fluorescence in situ hybridization analysis. Recent progre...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- BMC medicine Apr 11, 2026
Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.
Circulating tumor DNA (ctDNA) profiling offers a noninvasive approach to monitor minimal residual disease (MRD) and clonal evolution in diffuse large B-cell lymphoma (DLBCL). In this study, we analyzed 164 newly diagnosed DLBCL patients from the First Affiliated Hospital of Nanjing Medical Universit...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Mayo Clinic proceedings Apr 10, 2026
Treatment of Diffuse Large B-Cell Lymphoma.
Diffuse large B-cell lymphoma, the most common non-Hodgkin lymphoma subtype, represents 30% to 40% of cases globally. It is an aggressive but potentially curable malignant disease with substantial clinical and molecular heterogeneity. Gene expression profiling defines distinct molecular subtypes wit...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- European journal of haematology Apr 5, 2026
Frontline Therapy in Diffuse Large B-Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions.
Diffuse large B-cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R-CHOP has been the cornerstone of frontline treatment, curing approximately two-thirds of patients. Despit...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Cancer science Apr 2, 2026
Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
We conducted a phase 1b study evaluating safety and tolerability of tafasitamab, a CD19-targeting immunotherapy, in Japanese patients with B-cell non-Hodgkin lymphoma (NHL). Eligible patients were ≥ 18 years old with relapsed/refractory (R/R) B-cell NHL (Group 1), R/R diffuse la...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Blood cancer journal Mar 20, 2026
Current treatment algorithm: diffuse large B cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy and is the most common subtype of lymphoma. Treatment is administered with curative intent and approximately two thirds of patients are expected to have durable long-term survival. To achieve this, anthracycline-based chemother...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- American journal of hematology Mar 17, 2026
2026 Update on the Management of Diffuse Large B-Cell Lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R-CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola-R-CHP and R...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Cancer cell Mar 11, 2026
Axes of biological variation in diffuse large B cell lymphoma.
Genetic and gene expression subtypes of diffuse large B cell lymphoma (DLBCL) have been defined using bulk tumor analysis. To explore their biology, we derived single-cell RNA and ATAC sequencing data from 103 DLBCL biopsies and identified malignant B cells by their non-diploid DNA copy number profi...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- International journal of oncology Mar 7, 2026
Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).
Diffuse large B‑cell lymphoma (DLBCL), the most prevalent subtype of lymphoma, is characterized by rapid growth and a poor prognosis, with the R‑CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) being the standard first‑line therapy. However, 30...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Mar 5, 2026
Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma.
CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL), but challenges such as posttreatment failure and immune-related adverse events (AEs) persist. This study explores the gut microbiome as a predictive bio...
Why it matters: Recent peer-reviewed research on Diffuse large B-cell lymphoma that may be relevant for patients and caregivers.
More on Diffuse large B-cell lymphoma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.